Pharmacodynamic Biomarkers for Quantifying the Mycobacterial Effect of High Doses of Rifampin in Patients with Rifampin-susceptible Pulmonary Tuberculosis

BACKGROUND: Suboptimal drug exposure in patients with drug-susceptible tuberculosis (DS-TB) can drive treatment failure. Pharmacodynamics (PD) biomarkers such as the plasma TB drug-activity (TDA) assay may guide dose finding studies and predict microbiological outcomes differently than conventional...

Descripción completa

Detalles Bibliográficos
Autores principales: Said, Bibie N, Heysell, Scott K, Yimer, Getnet, Aarnoutse, Rob E., Kibiki, Gibson S, Mpagama, Stellah, Mbelele, Peter M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7612567/
https://www.ncbi.nlm.nih.gov/pubmed/34916467
http://dx.doi.org/10.4103/ijmy.ijmy_178_21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7612567/
https://www.ncbi.nlm.nih.gov/pubmed/34916467
http://dx.doi.org/10.4103/ijmy.ijmy_178_21

Ejemplares similares